Prescient Therapeutics Investor Briefing
Prescient Therapeutics CEO Steven Yatomi-Clarke is joined by special guests Professor Phil Darcy of the Peter MacCallum Cancer Centre and Dr Rebecca Lim, Precient’s Director of Scientific Affairs.
In this session, they discussed:
- PTX’s collaboration with Peter Mac
- Using OmniCAR’s unique features to create therapies where current generation CAR-Ts have struggled
- PTX’s three new next-gen CAR-T programs in hematological and solid cancers with massive addressable markets and unmet needs
Recorded on 1 July 2021 at 1pm (AEST)
Featured Speakers
Steven Yatomi-Clarke
CEO and Managing Director
Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.
Professor Phillip Darcy
Group Leader, Senior Faculty at Peter MacCallum Cancer Centre
Professor Phil Darcy is currently a NHMRC Senior Research Fellow and Group Leader at the Peter MacCallum Cancer Centre. His laboratory focuses on developing novel T cell based immunotherapy approaches for cancer in preclinical mouse models and translating this into patients. His laboratory is also focused on development of combined immune based therapies for cancer.
Dr Rebecca Lim
Director of Scientific Affairs at Prescient Therapeutics
Dr Rebecca Lim has over 10 years of experience in allogeneic cell therapies for regenerative medicine. She was previously the Scientific Director for the Cell Therapies Platform at the Hudson Institute and an Associate Professor at Monash University.
